Aleor Derma Karakhadi unit clears USFDA inspection
Mumbai: Drugmaker Alembic Pharma recently informed the bourses that its Joint Venture, Aleor Dermaceutical has successfully completed the US drug regulator's (USFDA) inspection.
"Aleor Dermaceuticals Ltd. (Aleor Derma), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat, India; without any observations, " Alembic said.
Also Read: Alembic Pharma clears USFDA inspection at Bioequivalence facility in Vadodara
The inspection was carried out from 6th January 2020 to 8th January 2020, it added.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. Alembic has a cumulative total of 110 Abbreviated New Drug Application (ANDA) approvals (97 final approvals and 13 tentative approvals) from USFDA.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd